COVID-19 Myocarditis
| Autor: | Eric Alter, Sophia Kwon, Sripal Bangalore, Anna Nolan |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Microbiology (medical)
2019-20 coronavirus outbreak Pediatrics medicine.medical_specialty Myocarditis Coronavirus disease 2019 (COVID-19) business.industry Mortality rate Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) medicine.medical_treatment Disease medicine.disease Infectious Diseases Pandemic Medicine Intubation business |
| Zdroj: | Infectious Diseases in Clinical Practice. 29:e414-e417 |
| ISSN: | 1536-9943 1056-9103 |
| DOI: | 10.1097/ipc.0000000000001016 |
| Popis: | Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), emerged in Wuhan, China, and rapidly led to a global pandemic that affected 213 countries, more than 5.8 million cases, and 360,000 deaths worldwide as of May 28, 2020. The United States currently has the highest number of COVID-19 cases in the world and contributes to nearly a third of the global death rate. The prevalence of COVID myocarditis is unclear but generally considered rare, with estimates up to 7% of COVID-related deaths. However, these patients suffered catastrophic worsening disease with respiratory compromise requiring intubation and often death. We report the case of a patient with COVID-19-induced myocarditis who was successfully treated with dexamethasone and review the literature. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|